

## **EnteroMedics narrows losses in Q3, aims for 2014 commercialization**

Mass Device

EnteroMedics narrows Q3 losses by 20%, with lower spending on research & development in the 3 months ended September 30.



[EnteroMedics](#) [1] (NSDQ:[ETRM](#) [2]) narrowed its losses during its 3rd quarter, cutting its research & development expenses nearly in half.

The weight-loss neurostimulation devices maker posted \$5.8 million in net losses, or 14¢ per share, 1¢ above the analysts' expectations. That compared with a net loss of \$7.3 million, or 26¢ per share, during the same period last year. No sales were reported for either term.

EnteroMedics, a development-stage company, is working on a device that stimulates the vagus nerve with high frequency, low energy electrical impulses in order to treat obesity.

**Source URL (retrieved on 01/30/2015 - 11:27pm):**

[http://www.mdtmag.com/news/2012/10/enteromedics-narrows-losses-q3-aims-2014-commercialization?qt-most\\_popular=0&qt-recent\\_content=0](http://www.mdtmag.com/news/2012/10/enteromedics-narrows-losses-q3-aims-2014-commercialization?qt-most_popular=0&qt-recent_content=0)

**Links:**

[1] <https://www.massdevice.com/company/enteromedics-inc>

[2] <http://www.google.com/finance?q=etrm>